Anti-Cyclic Citrullinated Peptide (Anti-CCP) and Anti-Mutated Citrullinated Vimentin (Anti-MCV) Relation with Extra-Articular Manifestations in Rheumatoid Arthritis

Table 6

Multivariate logistic regression testing for variables associated with ExRA.

Criterion predictor	Method Enter			Method forward stepwise
	OR	95% CI	𝑃	OR	95% CI	𝑃
Age, years	1.08	1.02–1.13	0.002	1.05	1.01–1.10	0.015
Disease duration, years	1.13	1.04–1.23	0.002	1.09	1.02–1.16	0.007
Smoke exposure	0.70	0.25–2.00	0.41	Not in the model	—	—
DAS-28	2.24	1.42–3.52	<0.001	1.86	1.27–2.73	0.002
Functional Impairment (HAQ-Di)	5.62	1.78–17.75	0.003	4.46	1.51–13.14	0.007
CRP mg/L	1.02	1.00–1.05	0.025	Not in the model	—	—
ESR mm/hr	0.95	0.90–0.99	0.02	Not in the model	—	—
RF IU/mL	1.27	0.45–3.54	0.64	Not in the model	—	—
Anti-CCP IU/mL	1.00	0.99–1.01	0.84	Not in the model	—	—
Anti-MCV IU/mL	1.00	0.99–1.002	0.63	Not in the model	—	—
Anti-TNF agents	1.63	0.36–7.50	0.53	Not in the model	—	—

DAS28: disease activity score 28-joints assessed; HAQ-Di: Health Assessment Questionnaire-Disability Index; MTX: methotrexate; Anti-CCP: anti-cyclic citrullinated peptide antibodies, OR: odds ratio, 95% CI, 95% confidential intervals.